Lipid profile

Avricore to Present at Emerging Growth Conference on Oct. 26, 2022

Retrieved on:

Friday, October 21, 2022

VANCOUVER, British Columbia, Oct. 21, 2022 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or AVCR) is excited to present at the Emerging Growth Conference on October 26th.

Key Points:

VANCOUVER, British Columbia, Oct. 21, 2022 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or AVCR) is excited to present at the Emerging Growth Conference on October 26th.
The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth.
Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.
Avricore Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward.

HealthTab™ Roll Out on Track and Operations Cashflow Positive

Retrieved on:

Tuesday, October 11, 2022

We are on track to achieve the late-November target for full deployment.

Key Points:

We are on track to achieve the late-November target for full deployment.
Once a pharmacy has HealthTab onsite there is a period of training and acclimating teams with the workflow.
In fact, HealthTab already has positive cash-flow from operations and is expected to significantly ramp up gross revenues over the next 12 months yielding target margins and profitability by Q2 2023.
These changes and commitments will have a significant impact on sales volumes in 2023, not to mention demand from pharmacy groups to install HealthTab.

Avricore Health Announces CEO Update Call on Sept. 22, 2022

Retrieved on:

Tuesday, September 20, 2022

Were currently deploying a significant expansion of HealthTab systems and were on track to achieve our revenue goals, as well as getting to cash flow positivity, said Avricore Health CEO, Hector Bremner.

Key Points:

Were currently deploying a significant expansion of HealthTab systems and were on track to achieve our revenue goals, as well as getting to cash flow positivity, said Avricore Health CEO, Hector Bremner.
Its an exciting time for the Company and were looking forward to discussing the recent successes and future objectives.
HealthTab is a turnkey point-of-care testing solution that combines best-in-class point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues.
Avricore Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward.

Avricore Health Supports the Globe and Mail’s Health Innovation Event

Retrieved on:

Monday, September 19, 2022

VANCOUVER, British Columbia , Sept. 19, 2022 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or AVCR) was honoured to join the Globe and Mails recent Health Care Innovation event, featuring leaders from various corners of the sector, including Company CEO, Hector Bremner.

Key Points:

VANCOUVER, British Columbia , Sept. 19, 2022 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or AVCR) was honoured to join the Globe and Mails recent Health Care Innovation event, featuring leaders from various corners of the sector, including Company CEO, Hector Bremner.
The Globe and Mails event featured health sector leaders, academics, governmental agency representatives, physicians, and patient advocates.
For a full list of participants and to watch the webcast in its entirety, it can be viewed at the Globe and Mails site at the following link: https://www.theglobeandmail.com/events/article-new-approaches-to-health-... .
Avricore Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward.

Global Clinical Chemistry Market (2022 to 2027) - Basic Metabolic Panel Tests Segment Hold Lion's Share - ResearchAndMarkets.com

Retrieved on:

Thursday, August 11, 2022

Furthermore, general testing, special tests, diagnostic tests, toxicological tests, urinalysis, and clinical endocrinology tests are all included in clinical chemistry.

Key Points:

Furthermore, general testing, special tests, diagnostic tests, toxicological tests, urinalysis, and clinical endocrinology tests are all included in clinical chemistry.
The total clinical chemistry market is predicted to grow in the future due to an increased desire for automated clinical chemistry techniques among healthcare and medical professionals.
Reagents Segment will Gain Market Share during the Forecast Period:
The clinical chemistry market is divided into analyzers and reagents based on product.
Basic Metabolic Panel Tests Segment Hold Lion's Share:
By Test Type, we have covered the market for Basic Metabolic Panel, Electrolyte Panel, Liver Panel, Lipid Profile, Renal Profile, Thyroid Function Panel, and Specialty Chemical tests.

Avricore Grants Options

Retrieved on:

Thursday, August 11, 2022

VANCOUVER, British Columbia, Aug. 10, 2022 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or AVCR) is pleased to announce that the Companys board of directors has approved the granting of stock options (the Options) exercisable for a total of 2,725,000 common shares to its directors, officers, and consultants at an exercise price of CAD$0.15 per common share.

Key Points:

VANCOUVER, British Columbia, Aug. 10, 2022 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or AVCR) is pleased to announce that the Companys board of directors has approved the granting of stock options (the Options) exercisable for a total of 2,725,000 common shares to its directors, officers, and consultants at an exercise price of CAD$0.15 per common share.
The options are subject to a 1-year vesting period, with of the options vesting 3 months after the date of the grant and the remaining options vesting on a quarterly basis thereafter.
The options expire 5 years from the date of the grant, subject to the optionees continuing to act as directors, officers or consultants of the Company.
Avricore Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward.

Healthtab™ Expands With Shoppers Drug Mart®

Retrieved on:

Monday, August 8, 2022

In addition to Shoppers Drug Mart pharmacies, this new MSA and corresponding Statement of Work (SOW) provides for affiliated locations under the Loblaw family of brands, to utilize HealthTab upon request.

Key Points:

In addition to Shoppers Drug Mart pharmacies, this new MSA and corresponding Statement of Work (SOW) provides for affiliated locations under the Loblaw family of brands, to utilize HealthTab upon request.
Announced in the summer of 2021 a signed MSA with Shoppers Drug Mart Inc. to pilot the HealthTab platform in 11 locations, allowing patients access to point-of-care blood screening and health-data management of potential risks for developing diabetes and cardiovascular conditions through the HealthTab-integrated Afinion 2 analyzers by Abbott Rapid Diagnostics.
HealthTab has already been deployed in 104 Shoppers Drug Mart pharmacies across British Columbia, New Brunswick, Nova Scotia and Ontario.
Approved tests include glucose, HbA1c and lipids, all of which HealthTab currently offers with the Abbott Afinion 2.

Avricore Health Executing Growth Strategy - Summer 2022 Corporate Update

Retrieved on:

Thursday, June 2, 2022

VANCOUVER, British Columbia, June 02, 2022 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or AVCR) is pleased to provide this corporate update on the Companys activities and progress in the first five months of 2022, as well as an outlook on the Companys objectives and expectations for the balance of the year.

Key Points:

VANCOUVER, British Columbia, June 02, 2022 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or AVCR) is pleased to provide this corporate update on the Companys activities and progress in the first five months of 2022, as well as an outlook on the Companys objectives and expectations for the balance of the year.
HealthTab is a turnkey point-of-care testing solution that combines best-in-class point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues.
It gives knowledgeable and trusted pharmacists a greater role in primary care delivery, while empowering patients to take more control of their health.
Avricore Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward.

Avricore Health CEO Hosts Investor Call December 15th

Retrieved on:

Thursday, December 9, 2021

Blood, Pharmacy, GLOBE, Review, Health, API, Point-of-care testing, Patient, Biomarker, Lipid profile, Glycated hemoglobin, COVID-19, Pharmacist, Conditional sentence, Strep, RWD, EGFR, Pharmaceutical industry

VANCOUVER, British Columbia, Dec. 09, 2021 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or AVCR) will host a year end update and look ahead discussion by the Companys CEO and key team members.

Key Points:

VANCOUVER, British Columbia, Dec. 09, 2021 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or AVCR) will host a year end update and look ahead discussion by the Companys CEO and key team members.
Weve had our best year yet, despite many external factors that created headwinds, and were extremely excited to head into 2022, said Avricore Health CEO, Hector Bremner.
Given that we are well capitalized and have executed several key agreements already, were well positioned for growth.
Avricore Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward.

HealthTab™ to Offer Abbott’s i-STAT Alinity™, Expanding Chronic Disease Testing to Select Community Pharmacies in Canada

Retrieved on:

Tuesday, November 23, 2021

The agreement allows HealthTab to distribute Abbotts point-of-carei-STAT Alinity and its associated tests for creatinine in Canadian pharmacies to better support patients with important information about their renal function.

Key Points:

The agreement allows HealthTab to distribute Abbotts point-of-carei-STAT Alinity and its associated tests for creatinine in Canadian pharmacies to better support patients with important information about their renal function.
Understanding renal function in patients at risk from or already living with chronic disease is critical, said Hector Bremner, CEO of Avricore Health.
Bringing high-quality point-of-care testing to pharmacists, HealthTab deployed Afinion 2 in select Shoppers Drug Mart pharmacies earlier this year as part of an initiative to screen for and support patients living with diabetes.
HealthTab is a turnkey point-of-care testing solution that combines best-in-class point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues.